Original from: ADVFN
Genedrive (LSE:GDR) has entered into a collaboration agreement with Thermo Fisher Scientific to develop the Genedrive CYP2C19 HT Kit, a high-throughput pharmacogenetic in vitro diagnostic test designed for use on Thermo Fisher’s QuantStudio 5 Dx PCR platform. The new assay is aimed at centralised laboratory testing and complements the company’s existing rapid CYP2C19 ID Kit for near-patient use. Genedrive is targeting UKCA certification by the end of 2026, with the initial commercial focus on NHS genomic laboratories across the UK.
The CYP2C19 HT Kit has been designed to support high-volume laboratory workflows through a multiplex PCR assay that operates directly from blood samples without the need for nucleic acid extraction. The test also features a broad allele panel to improve ethnic inclusivity and is supplied in a lyophilised format to simplify laboratory processes while reducing consumable requirements. By expanding its CYP2C19 product range into the central laboratory market, Genedrive aims to capitalise on growing clinical demand driven by recommendations from NICE and the American Heart Association for CYP2C19 genotyping in stroke and cardiovascular care. The collaboration also provides access to Thermo Fisher’s extensive installed base of diagnostic platforms, opening the door to a broader addressable market.
Despite the strategic opportunity, Genedrive’s investment outlook remains constrained by its financial position. The company continues to report significant losses, ongoing cash burn and a declining equity base, although it maintains relatively low debt levels. Technical indicators provide some support, with the shares trading above key moving averages and momentum remaining broadly neutral. However, valuation remains difficult to assess due to negative earnings and the absence of a dividend yield.
More about Genedrive
Genedrive plc is a UK-based commercial-stage diagnostics company specialising in rapid pharmacogenetic testing that supports safer and more effective prescribing in emergency and acute care settings. Its proprietary platform powers two CE-IVD-approved and NICE-recommended diagnostic tests already used within the NHS: the Genedrive CYP2C19 ID Kit, which identifies stroke patients less likely to respond to clopidogrel, and the MT-RNR1 ID Kit, designed to prevent antibiotic-induced hearing loss in newborns. The company is focused on expanding the adoption of precision diagnostics across routine clinical practice in the UK and international markets.
Source: Genedrive Partners with Thermo Fisher to Expand CYP2C19 Diagnostic Portfolio (GDR)
